XRHealth, a provider of telehealth-enabled immersive virtual reality (VR) and extended reality (XR) therapeutics, announced the acquisition of all assets of NeuroReality, including their main product “Koji’s Quest,” a digital rehabilitative therapeutic offered through immersive extended reality gameplay.
The financial terms of the acquisition were not disclosed.
NeuroReality has raised a total of €800K in Pre-Seed funding to date.
NeuroReality provides a range of cognitive virtual reality therapeutics, including ‘Koji’s Quest,’ a customizable digital health program designed to support rehabilitation for stroke, traumatic brain injury, neurodevelopmental and neurodegenerative conditions, dementia, and healthy aging.
Commenting on the acquisition, Eran Orr, CEO of XRHealth, said: “The acquisition of NeuroReality and its flagship product, Koji’s Quest, represents another leap forward in our mission to provide the most comprehensive XR therapeutic platform available. We are focused on creating a transformative experience for patients and clinicians alike, and Koji’s Quest will allow us to offer an even richer, more engaging set of tools for therapy and rehabilitation.”
Last year, XRHealth acquired Barcelona-based Amelia Virtual Care (a VR platform for mental health professionals, with an intention to merge into one company under the XRHealth brand name). The merger was facilitated by Asabys Partners, a Barcelona-based venture capital firm specializing in health innovation and deep tech supported by Alantra and Banc Sabadell, and legacy investor at Amelia Virtual Care.
XRHealth has raised a total of $41 million in funding to date. Their most recent funding round of $6 million, led by Asabys Partners with participation from NOVA Prime Fund and existing investors, was completed in January this year.
For more information, click here to read the official press release…